Top

Published in:

Open Access 01-01-2020 | Cytostatic Therapy | ASO Author Reflections

ASO Author Reflections: Can Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy be Improved?

Authors: Wilhelm Graf, MD, PhD, Helgi Birgisson, MD, PhD

Published in: Annals of Surgical Oncology | Issue 1/2020

Excerpt

Despite improving median and 5-year survival in patients with peritoneal surface malignancy originating from the large bowel, a substantial proportion experience rapid disease progression after seemingly radical cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Some of these patients have low Peritoneal Cancer Index (PCI). Various more or less fruitful attempts have been undertaken to predict outcome but, to date, reliable measures are insufficient. Among useful predictive tools are extent of peritoneal dissemination, signet cell differentiation, and colorectal peritoneal (COREP) score.1^–3 …

Goéré D, Souadka A, Faron M, Cloutier AS, Viana B, Honoré C, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22:2958–64.CrossRef

Solomon D, DeNicola N, Feingold D, Liu PH, Aycart S, Golas BJ, et al.Signet ring cell features with peritoneal carcinomatosis in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are associated with poor overall survival. J Surg Oncol. 2019;119(6):758–65.CrossRef

Cashin PH, Graf W, Nygren P, Mahteme H. Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an observational cohort study. Ann Surg. 2012;256(6):1078–83.CrossRef

Graf W, Cashin PH, Ghanipour L, Enblad M, Botling J, Terman A, et al. Prognostic impact of BRAF and KRAS mutation in patients with colorectal and appendiceal peritoneal metastases scheduled for CRS and HIPEC. Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-019-07452-2.

Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7 [abstract]. J Clin Oncol. 2018;36:18.CrossRef

Title: ASO Author Reflections: Can Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy be Improved?
Authors: Wilhelm Graf, MD, PhD
Helgi Birgisson, MD, PhD
Publication date: 01-01-2020
Publisher: Springer International Publishing
Keyword: Cytostatic Therapy
Published in: Annals of Surgical Oncology / Issue 1/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-019-07664-6

At a glance: The STEP trials

Springer Medicine

ASO Author Reflections: Can Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy be Improved?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

The Sunbelt Melanoma Trial

Crohn’s-Like Lymphoid Reaction is Associated with Oncological Prognosis and Nutritional Status in Patients with Pathological Stage II/III Gastric Cancer

Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)

Diaphragmatic Peritoneal Stripping Versus Full-Thickness Resection in CRS/HIPEC: Is There a Difference?

Desmoplastic Small Round Cell Tumor: Long-Term Complications After Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy

Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases